SVF Vaccines
Address: Stockholm,About Us
SVF is developing a novel platform for vaccines and imunnetherapies that could be administrated as DNA, proteinbased or RNA. Our first candidates targets disease areas with a high unmet medical need Hepatitis B(HBV), Hepatitis D(HDV) and corona viruses with targeted indications: HDV therapeutic vaccine HDV prophylactic vaccine HBV therapeutic vaccine Corona viruss prophylactic vaccine HDV: Aprox 12M carriers worldwide and increasing prevalence in the EU, 3-5% prevalence among HBV carriers and >15% in HBV patients visiting specialist clinics. Main course to cirrhosis and liver cancer. No preventive vaccine available and very limited treatment options. Potential as Orphan drug and fast track designation. Significant commercial potenital HBV: Huge population (300M), even small at-high-risk segments have significant commercial potential. Targeting patients already under care on existing treatments. Untreated HBV causes cirrhosis and liver cancer with high costs for patients as well as health care coronavirus: ongoing pandemic with a high unmet need. SVF strategy is to make the vaccine future proof towards other coronaviruses than Sars-Cov2 SVF has experienced expertise of top researchers on viral hepatitis vaccines and immunotherapies and a strong track record of launching several” first in class” drugs at big pharma companies in its team. If you have any questions, please contact us:
Sectors
- Collaborations & Partnerships- R&D
- Proprietary Research & Manufacture
Categories
- Anti-Virals
- Platform Technology-Drug Discovery
- Clinical Development-Pipeline
- Immunotherapy
- Immunology
- Vaccine Products
News
SVF Vaccines partners with Touchlight to accelerate SVF 001 toward clinical development
SVF Vaccines AB (“SVF Vaccines” or the “Company”), a Swedish biotechnology company developing vaccines and immunotherapies for serious infectious diseases, today announced a collaboration with Touchlight, a biotechnology company specialising in cell-free DNA manufacturing, to accelerate the continued advancement of the Company’s lead hepatitis B/D immunotherapy program, SVF-001, toward clinical development.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com